Sažetak | CILJ ISTRAŽIVANJA:
Pokazati postoje li statistički značajne razlike u duljini latencije vala P300 ciljanog i
neciljanog podražaja i amplitudi vala P300 ciljanog i neciljanog podražaja između skupine
ispitanika s multiplom sklerozom (MS) i kontrolne skupine.
ISPITANICI I METODE:
Studija je napravljena kao presječno istraživanje. Provedena je u Referentnom centru za
evocirane potencijale ministarstva zdravlja Republike Hrvatske, Klinici za neurologiju KBC-a
Split. Podatci su prikupljani u vremenu od 1. siječnja 2012. godine do 1. svibnja 2013. godine.
U istraživanje je uključeno 14 ispitanika oboljelih od MS, kojima je pridružena kontrolna
skupina od 14 ispitanika s urednim neurološkim razvojem koji po dobnim i spolnim
karakteristikama odgovaraju ispitivanoj skupini. Nakon pregleda medicinske dokumentacije
te analize kriterija uključenja i isključenja obje skupine ispitanika podvrgnute su na jednak
način ispitivanju slušnog kognitivnog potencijala (val P300).
REZULTATI:
Nismo dokazali statistički značajnu razliku medijana duljine latencije vala P300 ciljanog
podražaja između ispitanika s multiplom sklerozom (MS) i kontrolne skupine (P=0,473).
Medijan duljine latencije vala P300 ciljanog podražaja u ispitanika s MS bio je 301 ms (minmaks: 292-318 ms), dok je medijan duljine latencije vala P300 ciljanog podražaja u
kontrolnoj skupini bio 300,5 ms (min-maks: 295-306 ms). Dokazali smo da postoji statistički
značajna razlika medijana duljine latencije vala P300 neciljanog podražaja između
istraživanih skupina. Medijan duljine latencije vala P300 neciljanog podražaja u ispitanika s
MS bio je 318 ms (min-maks: 295-361 ms), dok je medijan duljine latencije vala P300
neciljanog podražaja u kontrolnoj skupini bio 300 ms (min-maks: 293-305 ms) (P<0,001).
Analizirajući amplitudu vala P300 neciljanog podražaja u skupini ispitanika oboljelih od MS
od 14 ispitanika njih 12 imalo je patološki nalaz, a u kontrolnoj je samo 1 imao patološki
nalaz, što upućuje na evidentnu razliku dviju skupina. Analizirajući amplitudu vala P300
ciljanog podražaja u skupini ispitanika oboljelih od MS njih 7 je imalo uredan nalaz, a 7
patološki nalaz, dok je u kontrolnoj skupini njih 13 imalo je uredan nalaz (P=0,016).
ZAKLJUČCI:
Bolesnici oboljeli od multiple skleroze nemaju produljenu latenciju vala P300 ciljanog
podražaja u odnosu na kontrolnu skupinu, ali imaju sniženu amplitudu vala P300 ciljanog
podražaja, te produljenu latenciju i sniženu amplitudu vala P300 neciljanog podražaja. |
Sažetak (engleski) | OBJECTIVES:
Show whether there is a statistically significant difference in length of the P300 wave latency
of targeted and untargeted stimulus and statistically significant difference in the P300 wave
amplitude of targeted and untargeted stimulus between group of patients with multiple
sclerosis (MS) and control group.
PATIENTS AND METHODES:
The study was designed as a cross-sectional study. Conducted at the Reference Centre for
evoked potentials Ministry of Health of the Republic of Croatia, Department of Neurology,
University Hospital Split. Data were collected in the period from January 1st 2012. until May
1st 2013. The study included 14 patients suffering from MS, which is associated with a control
group of 14 subjects with normal neurological development. Control group coincided with the
test group by age and sex characteristics. After reviewing the medical records and analyzes
the inclusion and exclusion criteria, both groups were subjected to the same procedure
examining auditory cognitive potentials (P300 wave).
RESULTS:
We didnt demonstrate a statistically significant difference in the median length of the P300
wave latency of target stimulus between patients with MS and control group. The median
length of the P300 wave latency of target stimulus in patients with MS was 301 ms (min-max:
292-318 ms), and the median length of the P300 wave latency of target stimuli in the control
group was 300,5 ms (min-max: 295 -306 ms) (P= 0,473). We have shown that there is a
statistically significant difference of the median length of P300 wave latency of untargeted
stimulus between this two groups. The median length of the P300 wave latency of untargeted
stimulus in patients with MS was 318 ms (min-max: 295-361 ms), and the median length of
the P300 wave latency of untargeted stimulus in the control group was 300 ms (min-max:
293-305 ms) (P<0,001). By analyzing the P300 wave amplitude of untargeted stimulus in
the group of patients suffering from MS of 14 patients, 12 had abnormal findings, in the
control group only 1 had abnormal findings, suggesting the obvious differences between the
two groups. By analyzing the P300 wave amplitude of target stimulus in a group of patients
suffering from MS, 7 of them had normal findings, and 7 abnormal, whereas in the control
group, 13 of them had normal findings (P = 0,016).
CONCLUSIONS:
Patients suffering from multiple sclerosis dont have prolonged the P300 wave latency of
target stimulus compared to the control group, but they have reduced the P300 wave
amplitude of target stimulus, and prolonged latency and reduced amplitude of the P300 wave
of untargeted stimulus. |